Merck
Merck Reports Strong Q3 Results but Lowers Full-Year Sales Guidance
Merck, Q3 Results, Full-Year Sales Guidance, Keytruda, Gardasil, Januvia, Winrevair, Capvaxive
Merck Acquires “Chameleon” Approach to Combat Deadly Brain Cancers for $30 Million
Merck, brain cancer, chameleon approach, $30 million, pharmaceutical acquisition
Breakthroughs in RSV Prevention: Merck and Pfizer Report High Efficacy Rates
RSV prevention, Merck, Pfizer, clesrovimab, ABRYSVO, respiratory syncytial virus, monoclonal antibodies, vaccines
Merck Halts Two Phase 3 Trials of Keytruda for Early-Stage Lung and Skin Cancers
Merck, Keytruda, Phase 3 trials, early-stage lung cancer, skin cancer, KEYNOTE-867, KEYNOTE-630
Merck’s WINREVAIR Receives EU Approval for Pulmonary Arterial Hypertension Treatment
WINREVAIR, Merck, EU Approval, Pulmonary Arterial Hypertension, PAH Treatment
FDA to Reassess Use of PD-1 Inhibitors in Stomach Cancer, Seeking Expert Input on Merck, BMS, and BeiGene Medications
FDA, PD-1 inhibitors, stomach cancer, Merck, BMS, BeiGene, Oncologic Drugs Advisory Committee, PD-L1 expression
Merck’s Ebola Vaccine Demonstrates 84% Effectiveness in Real-World Setting During DRC Outbreak
Ebola vaccine, Merck, Ervebo, effectiveness, real-world analysis, DRC outbreak, vaccination, public health.
Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti
Merck Acquires Clinical-Stage CD3xCD19 Bispecific Antibody for $700M
Merck, CD3xCD19 bispecific antibody, Curon Biopharmaceutical, clinical-stage, pharmaceutical acquisition
Merck and Daiichi Sankyo Collaborate to Develop T-Cell Engager MK-6070 from Harpoon Acquisition
Merck, Daiichi Sankyo, T-cell engager, MK-6070, Harpoon Therapeutics, small cell lung cancer, DLL3, antibody-drug conjugates